Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer.

[1]  E. Sturgis,et al.  Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. , 2018, Thyroid : official journal of the American Thyroid Association.

[2]  I. Ganly,et al.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[3]  R. Peeters,et al.  Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[4]  P. Soares,et al.  TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma , 2018, Endocrine.

[5]  Dong Jin Lee,et al.  The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis , 2018, World Journal of Surgery.

[6]  L. Boucai,et al.  Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence , 2018, The Journal of clinical endocrinology and metabolism.

[7]  Nancy D Perrier,et al.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2018, CA: a cancer journal for clinicians.

[8]  S. Roman,et al.  Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts. , 2017, Thyroid : official journal of the American Thyroid Association.

[9]  Jee Soo Kim,et al.  Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. , 2017, Oral oncology.

[10]  Nancy D Perrier,et al.  Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? , 2017, Thyroid : official journal of the American Thyroid Association.

[11]  Shujun Cheng,et al.  TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer , 2017, The Journal of Nuclear Medicine.

[12]  Tao Zhang,et al.  Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality , 2017, JAMA oncology.

[13]  R. Tuttle,et al.  Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. , 2016, The Journal of clinical endocrinology and metabolism.

[14]  J. Shah,et al.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. , 2016, Thyroid : official journal of the American Thyroid Association.

[15]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[16]  J. Bishop,et al.  BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Tuttle,et al.  Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. , 2013, Thyroid : official journal of the American Thyroid Association.

[18]  S. Larson,et al.  Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. , 2013, The Journal of clinical endocrinology and metabolism.

[19]  S. Mandel,et al.  The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. , 2012, Thyroid : official journal of the American Thyroid Association.

[20]  R. Tuttle,et al.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.

[21]  R. Tuttle,et al.  In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.

[22]  G. Cevenini,et al.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.

[23]  R. Tuttle,et al.  Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. , 2011, Seminars in nuclear medicine.

[24]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[25]  M. Luster,et al.  A comparison of prognostic classification systems for differentiated thyroid carcinoma , 2009, Clinical endocrinology.

[26]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[27]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[28]  J. Llamas-Elvira,et al.  Clinical and Pathological Factors Related to 18F-FDG-PET Positivity in the Diagnosis of Recurrence and/or Metastasis in Patients with Differentiated Thyroid Cancer , 2009, Annals of Surgical Oncology.

[29]  S. Larson,et al.  Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma , 2008, Cancer.

[30]  P. Ladenson,et al.  The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[31]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[32]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[33]  R. Kloos,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .

[34]  P. Ladenson,et al.  Prospective multicenter study of thyroid carcinoma treatment , 1998 .

[35]  P. Ladenson,et al.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.

[36]  B. O'Sullivan,et al.  A comparison of different staging systems predictability of patient outcome , 1997, Cancer.